These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15171646)

  • 1. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population].
    Fu LQ; Huang F; Wu DZ; Guo JH
    Yao Xue Xue Bao; 2004 Mar; 39(3):161-3. PubMed ID: 15171646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphism analysis of cytochrome P4502C19 in Chinese Uigur and Han populations.
    Niu CY; Luo JY; Hao ZM
    Chin J Dig Dis; 2004; 5(2):76-80. PubMed ID: 15612662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
    Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
    J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytochrome P450 2C19 gene polymorphism in 104 Chinese Zang volunteers].
    Ding HW; Dong WZ; Jiang ZG; Ma X
    Yi Chuan; 2004 Mar; 26(2):151-4. PubMed ID: 15639978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.
    Katsuki H; Nakamura C; Arimori K; Fujiyama S; Nakano M
    Eur J Clin Pharmacol; 1997; 52(5):391-6. PubMed ID: 9272410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C19 polymorphism as a predictor of personalized therapy in South Indian population.
    Siddapuram SP; Banerjee R; Tandan M; Prathap N; Mitnal S; Duvvuru NR
    J Assoc Physicians India; 2011 Aug; 59():490-3. PubMed ID: 21887904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
    Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
    J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations].
    Zhang S; Dong Z; Tang L; Zhou Q; Wu Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyp2c19 genotype and omeprazole hydroxylation phenotype in Chinese Li population.
    Wang JH; Li PQ; Fu QY; Li QX; Cai WW
    Clin Exp Pharmacol Physiol; 2007; 34(5-6):421-4. PubMed ID: 17439410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.
    Yin OQ; Wing YK; Cheung Y; Wang ZJ; Lam SL; Chiu HF; Chow MS
    J Clin Psychopharmacol; 2006 Aug; 26(4):367-72. PubMed ID: 16855453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misclassification of allele CYP2C19*10 as CY2C19*2 by a commonly used PCR-RFLP procedure.
    Rasmussen H; Werge T
    Genet Test; 2008 Mar; 12(1):57-8. PubMed ID: 18373404
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.
    Hu YR; Qiao HL; Kan QC
    Acta Pharmacol Sin; 2004 Aug; 25(8):986-90. PubMed ID: 15301728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population.
    Kubota T; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
    Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
    Brøsen K; de Morais SM; Meyer UA; Goldstein JA
    Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
    Hu YM; Mei Q; Xu XH; Hu XP; Hu NZ; Xu JM
    World J Gastroenterol; 2006 Aug; 12(29):4750-3. PubMed ID: 16937451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
    Zand N; Tajik N; Moghaddam AS; Milanian I
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allele and genotype frequency of CYP2C19 in a Tamilian population.
    Adithan C; Gerard N; Vasu S; Rosemary J; Shashindran CH; Krishnamoorthy R
    Br J Clin Pharmacol; 2003 Sep; 56(3):331-3. PubMed ID: 12919183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.
    Ieiri I; Kubota T; Urae A; Kimura M; Wada Y; Mamiya K; Yoshioka S; Irie S; Amamoto T; Nakamura K; Nakano S; Higuchi S
    Clin Pharmacol Ther; 1996 Jun; 59(6):647-53. PubMed ID: 8681489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.